HC Wainwright Has Pessimistic Outlook of UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of Unicycive Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.50 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q1 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.35) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at $0.92 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.98 EPS, FY2027 earnings at $1.98 EPS, FY2028 earnings at $1.19 EPS and FY2029 earnings at $1.34 EPS.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $0.52 on Friday. The company has a market capitalization of $61.76 million, a PE ratio of -0.53 and a beta of 2.15. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.45. The firm has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.57.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

Institutional Investors Weigh In On Unicycive Therapeutics

A number of institutional investors have recently modified their holdings of UNCY. Octagon Capital Advisors LP boosted its holdings in Unicycive Therapeutics by 16.8% during the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock valued at $7,942,000 after acquiring an additional 1,441,000 shares during the period. Acuta Capital Partners LLC boosted its stake in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock valued at $1,829,000 after purchasing an additional 323,801 shares during the period. Nantahala Capital Management LLC grew its holdings in shares of Unicycive Therapeutics by 268.5% in the fourth quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock valued at $8,253,000 after purchasing an additional 7,571,636 shares in the last quarter. Northern Trust Corp increased its stake in Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock worth $46,000 after buying an additional 34,183 shares during the period. Finally, Vivo Capital LLC increased its stake in Unicycive Therapeutics by 123.0% during the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock worth $7,918,000 after buying an additional 5,500,000 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.